SpyGlass Pharma, Inc. (SGP) - Total Assets
Based on the latest financial reports, SpyGlass Pharma, Inc. (SGP) holds total assets worth $243.43 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See today's stock price for SpyGlass Pharma, Inc. for real-time trading data and today's change.
SpyGlass Pharma, Inc. - Total Assets Trend (2023–2025)
This chart illustrates how SpyGlass Pharma, Inc.'s total assets have evolved over time, based on quarterly financial data. Also see cash flow conversion of SpyGlass Pharma, Inc. for how efficiently the company converts equity into cash flow.
SpyGlass Pharma, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
SpyGlass Pharma, Inc.'s total assets of $243.43 Million consist of 93.9% current assets and 6.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 83.2% |
| Accounts Receivable | $431.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2023–2025)
This chart illustrates how SpyGlass Pharma, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of SpyGlass Pharma, Inc. to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SpyGlass Pharma, Inc.'s current assets represent 93.9% of total assets in 2025, a decrease from 98.7% in 2023.
- Cash Position: Cash and equivalents constituted 83.2% of total assets in 2025, up from 38.5% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2023.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
SpyGlass Pharma, Inc. Competitors by Total Assets
Key competitors of SpyGlass Pharma, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
USA | $35.32 Million |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
USA | $1.15 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.77 Billion |
|
Absci Corp
NASDAQ:ABSI
|
USA | $195.59 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
SpyGlass Pharma, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 25.06 | 2.23 | 2.23 |
| Quick Ratio | 25.06 | 2.23 | 2.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $227.02 Million | $9.62 Million | $9.62 Million |
SpyGlass Pharma, Inc. - Advanced Valuation Insights
This section examines the relationship between SpyGlass Pharma, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.64 |
| Latest Market Cap to Assets Ratio | 7.30 |
| Asset Growth Rate (YoY) | 396.9% |
| Total Assets | $115.87 Million |
| Market Capitalization | $846.20 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values SpyGlass Pharma, Inc.'s assets at a significant premium (7.30x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: SpyGlass Pharma, Inc.'s assets grew by 396.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SpyGlass Pharma, Inc. (2023–2025)
The table below shows the annual total assets of SpyGlass Pharma, Inc. from 2023 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $115.87 Million | +396.90% |
| 2024-12-31 | $23.32 Million | -43.33% |
| 2023-12-31 | $41.15 Million | -- |
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intra… Read more